ResearcherMayo ClinicNo recent work listed
Taketo Matsunaga
Matched on OpenAlex author ID A5090665997. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 25
2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper
Papers 4
- Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. Co-author DOI 10.1007/s00423-019-01754-5↗
- S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000940↗
- Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000258↗
- Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study. Co-author DOI 10.1097/mpa.0000000000000393↗
Closest collaborators
The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Takao Ohtsuka · 4 shared papers, 2015–2019 · strength 0.21
- Paper Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. DOI 10.1007/s00423-019-01754-5↗
- Paper S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000000940↗
- Paper Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant panc… DOI 10.1097/mpa.0000000000000258↗
- Yusuke Watanabe · 3 shared papers, 2015–2019 · strength 0.15
- Paper Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. DOI 10.1007/s00423-019-01754-5↗
- Paper Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant panc… DOI 10.1097/mpa.0000000000000258↗
- Paper Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study. DOI 10.1097/mpa.0000000000000393↗
- Yoshihiro Miyasaka · 3 shared papers, 2015–2019 · strength 0.15
- Paper Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. DOI 10.1007/s00423-019-01754-5↗
- Paper Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant panc… DOI 10.1097/mpa.0000000000000258↗
- Paper Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study. DOI 10.1097/mpa.0000000000000393↗
- Yoshinao Oda · 3 shared papers, 2015–2017 · strength 0.14
- Paper S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000000940↗
- Paper Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant panc… DOI 10.1097/mpa.0000000000000258↗
- Paper Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study. DOI 10.1097/mpa.0000000000000393↗
- Hideyo Kimura · 3 shared papers, 2015–2017 · strength 0.14
- Paper S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000000940↗
- Paper Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant panc… DOI 10.1097/mpa.0000000000000258↗
- Paper Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study. DOI 10.1097/mpa.0000000000000393↗
- Noboru Ideno · 3 shared papers, 2015–2017 · strength 0.14
- Paper S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000000940↗
- Paper Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant panc… DOI 10.1097/mpa.0000000000000258↗
- Paper Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study. DOI 10.1097/mpa.0000000000000393↗
- Masao Tanaka · 3 shared papers, 2015–2017 · strength 0.14
- Paper S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000000940↗
- Paper Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant panc… DOI 10.1097/mpa.0000000000000258↗
- Paper Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study. DOI 10.1097/mpa.0000000000000393↗
- Masafumi Nakamura · 2 shared papers, 2017–2019 · strength 0.13
- Kenoki Ohuchida · 2 shared papers, 2015–2017 · strength 0.10
- Junji Ueda · 2 shared papers, 2015 · strength 0.08
- Paper Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant panc… DOI 10.1097/mpa.0000000000000258↗
- Paper Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study. DOI 10.1097/mpa.0000000000000393↗
- Koji Tamura · 2 shared papers, 2015 · strength 0.08
- Paper Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant panc… DOI 10.1097/mpa.0000000000000258↗
- Paper Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study. DOI 10.1097/mpa.0000000000000393↗
- Akira Chikamoto · 1 shared paper, 2019 · strength 0.07
- Kazuyoshi Nishihara · 1 shared paper, 2019 · strength 0.07
- Shoji Natsugoe · 1 shared paper, 2019 · strength 0.07
- Hiroaki Nagano · 1 shared paper, 2019 · strength 0.07
- Hiroshi Kurahara · 1 shared paper, 2019 · strength 0.07
- Susumu Eguchi · 1 shared paper, 2019 · strength 0.07
- Naoya İmamura · 1 shared paper, 2019 · strength 0.07
- Masafumi Inomata · 1 shared paper, 2019 · strength 0.07
- Hirokazu Noshirο · 1 shared paper, 2019 · strength 0.07
- Hideo Baba · 1 shared paper, 2019 · strength 0.07
- Yasuhisa Mori · 1 shared paper, 2017 · strength 0.06
- Sushovan Guha · 1 shared paper, 2017 · strength 0.06
- Massimo Raimondo · 1 shared paper, 2017 · strength 0.06
- Hisato Igarashi · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.